Drug intelligence / Profile preview

JUVIAGEL

Development stage
Unknown
Lead developer
FEMPHARMA
Modality
Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration
Topical, Vaginal
01

Overview

JUVIAGEL (also known as FUNGIA) is a zinc-containing vaginal hydrogel developed by FEMPHARMA for the treatment and prevention of recurrent vulvovaginal candidiasis (VVC). The product contains zinc sulfate heptahydrate at a concentration of 20 mM. Its mechanism of action involves targeting the pH-regulated antigen 1 (Pra1) protein produced by *Candida albicans*. Pra1 is a fungal zincophore that, in zinc-limited environments such as the vaginal mucosa during infection, triggers a robust host inflammatory response characterized by neutrophil recruitment, which causes the burning and itching symptoms of yeast infections. By providing a local source of zinc, JUVIAGEL suppresses the expression of the Pra1 protein, thereby blocking the inflammatory cascade and preventing reinfection. Clinical data has demonstrated significant efficacy in preventing recurrent infections in women over a three-month period.

Brand names
JUVIAGEL
Other names
zinc-containing vaginal gelPra1 protein-zinc-containing vaginal gelPra-1 protein-zinc-containing vaginal gelPra 1 protein-zinc-containing vaginal gel
02

Targets

Pra1 (pH-regulated antigen 1)

Beyond the preview

Go deeper on JUVIAGEL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JUVIAGEL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call